Nurix Therapeutics, Inc. stock slid 40% after promising NX-5948 results in CLL. NX-5948 shows efficacy in heavily pre-treated ...

Panelists discuss how data from Mansour and colleagues suggesting potential Bruton tyrosine kinase (BTK) inhibitor ...

Panelists discuss how challenges in implementing emerging Bruton tyrosine kinase inhibitor (BTKi) regimens for treatment-naive patients with chronic lymphocytic leukemia (CLL) and mantle cell ...

In the trial, MCL patients with prior BTKi treatment showed a complete response rate of 71%, while the overall response rate ...

According to Mustang Bio: All ten patients in the study were previously treated with Bruton’s tyrosine kinase inhibitors (“BTKi”), and their disease continued to progress while on BTKi.